Conclusion
Patients with CF who have received a liver transplant may be initiated on elx/tez/iva with demonstrated safety and clinical efficacy. Frequent LFT monitoring is warranted and can be used to guide elx/tez/iva dose titrations. Early and close therapeutic drug monitoring of immunosuppression is important to ensure safety and efficacy of the regimen. Additional research is necessary to determine long term safety and efficacy of elx/tez/iva in patients with CF status-post liver transplantation.